IBDEI27B ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,37337,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37337,1,3,0)
 ;;=3^Fibromyalgia
 ;;^UTILITY(U,$J,358.3,37337,1,4,0)
 ;;=4^M79.7
 ;;^UTILITY(U,$J,358.3,37337,2)
 ;;=^46261
 ;;^UTILITY(U,$J,358.3,37338,0)
 ;;=M06.4^^140^1787^164
 ;;^UTILITY(U,$J,358.3,37338,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37338,1,3,0)
 ;;=3^Inflammatory polyarthropathy
 ;;^UTILITY(U,$J,358.3,37338,1,4,0)
 ;;=4^M06.4
 ;;^UTILITY(U,$J,358.3,37338,2)
 ;;=^5010120
 ;;^UTILITY(U,$J,358.3,37339,0)
 ;;=M54.5^^140^1787^191
 ;;^UTILITY(U,$J,358.3,37339,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37339,1,3,0)
 ;;=3^Low back pain
 ;;^UTILITY(U,$J,358.3,37339,1,4,0)
 ;;=4^M54.5
 ;;^UTILITY(U,$J,358.3,37339,2)
 ;;=^5012311
 ;;^UTILITY(U,$J,358.3,37340,0)
 ;;=M35.5^^140^1787^195
 ;;^UTILITY(U,$J,358.3,37340,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37340,1,3,0)
 ;;=3^Multifocal fibrosclerosis
 ;;^UTILITY(U,$J,358.3,37340,1,4,0)
 ;;=4^M35.5
 ;;^UTILITY(U,$J,358.3,37340,2)
 ;;=^5011794
 ;;^UTILITY(U,$J,358.3,37341,0)
 ;;=M79.1^^140^1787^196
 ;;^UTILITY(U,$J,358.3,37341,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37341,1,3,0)
 ;;=3^Myalgia
 ;;^UTILITY(U,$J,358.3,37341,1,4,0)
 ;;=4^M79.1
 ;;^UTILITY(U,$J,358.3,37341,2)
 ;;=^5013321
 ;;^UTILITY(U,$J,358.3,37342,0)
 ;;=G73.7^^140^1787^197
 ;;^UTILITY(U,$J,358.3,37342,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37342,1,3,0)
 ;;=3^Myopathy in diseases classified elsewhere
 ;;^UTILITY(U,$J,358.3,37342,1,4,0)
 ;;=4^G73.7
 ;;^UTILITY(U,$J,358.3,37342,2)
 ;;=^5004103
 ;;^UTILITY(U,$J,358.3,37343,0)
 ;;=M71.50^^140^1787^66
 ;;^UTILITY(U,$J,358.3,37343,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37343,1,3,0)
 ;;=3^Bursitis, NEC, unspec site, oth
 ;;^UTILITY(U,$J,358.3,37343,1,4,0)
 ;;=4^M71.50
 ;;^UTILITY(U,$J,358.3,37343,2)
 ;;=^5013190
 ;;^UTILITY(U,$J,358.3,37344,0)
 ;;=E83.59^^140^1787^104
 ;;^UTILITY(U,$J,358.3,37344,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37344,1,3,0)
 ;;=3^Disorders of calcium metabolism, oth
 ;;^UTILITY(U,$J,358.3,37344,1,4,0)
 ;;=4^E83.59
 ;;^UTILITY(U,$J,358.3,37344,2)
 ;;=^5003006
 ;;^UTILITY(U,$J,358.3,37345,0)
 ;;=L93.2^^140^1787^187
 ;;^UTILITY(U,$J,358.3,37345,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37345,1,3,0)
 ;;=3^Local lupus erythematosus, oth
 ;;^UTILITY(U,$J,358.3,37345,1,4,0)
 ;;=4^L93.2
 ;;^UTILITY(U,$J,358.3,37345,2)
 ;;=^5009469
 ;;^UTILITY(U,$J,358.3,37346,0)
 ;;=L40.59^^140^1787^209
 ;;^UTILITY(U,$J,358.3,37346,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37346,1,3,0)
 ;;=3^Psoriatic arthropathy, oth
 ;;^UTILITY(U,$J,358.3,37346,1,4,0)
 ;;=4^L40.59
 ;;^UTILITY(U,$J,358.3,37346,2)
 ;;=^5009170
 ;;^UTILITY(U,$J,358.3,37347,0)
 ;;=M1A.40X1^^140^1787^155
 ;;^UTILITY(U,$J,358.3,37347,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37347,1,3,0)
 ;;=3^Gout, chron, secndry, unspec site, w/ tophus, oth
 ;;^UTILITY(U,$J,358.3,37347,1,4,0)
 ;;=4^M1A.40X1
 ;;^UTILITY(U,$J,358.3,37347,2)
 ;;=^5010994
 ;;^UTILITY(U,$J,358.3,37348,0)
 ;;=D89.89^^140^1787^103
 ;;^UTILITY(U,$J,358.3,37348,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37348,1,3,0)
 ;;=3^Disorders invlvng immune mechanism, NEC, oth, spec
 ;;^UTILITY(U,$J,358.3,37348,1,4,0)
 ;;=4^D89.89
 ;;^UTILITY(U,$J,358.3,37348,2)
 ;;=^5002458
 ;;^UTILITY(U,$J,358.3,37349,0)
 ;;=M12.30^^140^1787^199
 ;;^UTILITY(U,$J,358.3,37349,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37349,1,3,0)
 ;;=3^Palindromic rheumatism, unspec site
 ;;^UTILITY(U,$J,358.3,37349,1,4,0)
 ;;=4^M12.30
 ;;^UTILITY(U,$J,358.3,37349,2)
 ;;=^5010570
 ;;^UTILITY(U,$J,358.3,37350,0)
 ;;=M35.3^^140^1787^203
